Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135653600> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2135653600 endingPage "696" @default.
- W2135653600 startingPage "696" @default.
- W2135653600 abstract "In the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial, bivalirudin with provisional glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition was found to be noninferior to heparin plus planned Gp IIb/IIIa blockade in the prevention of acute ischemic end points and was associated with significantly less bleeding by 30 days after percutaneous coronary intervention (PCI).To determine whether the efficacy of bivalirudin remains comparable with that of heparin plus Gp IIb/IIIa blockade over 6 months and 1 year.Follow-up study to 1 year of a randomized, double-blind trial conducted among 6010 patients undergoing urgent or elective PCI at 233 community or referral hospitals in 9 countries from October 2001 through August 2002.Patients were randomly assigned to receive intravenously bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg per hour for the duration of PCI), with provisional Gp IIb/IIIa inhibition, or to receive heparin (65 U/kg bolus), with planned Gp IIb/IIIa inhibition (abciximab or eptifibatide). Both groups received daily aspirin and a thienopyridine for at least 30 days after PCI.Incidence of death, myocardial infarction, or repeat revascularization by 6 months and death by 12 months after enrollment.At 6 months, death occurred in 1.4% of patients in the heparin plus Gp IIb/IIIa group and in 1.0% of patients in the bivalirudin group (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.43-1.14; P =.15). Myocardial infarction occurred in 7.4% and 8.2% of patients, respectively (HR, 1.12; 95% CI, 0.93-1.34; P =.24), and repeat revascularization was required in 11.4% and 12.1% of patients, respectively (HR, 1.06; 95% CI, 0.91-1.23; P =.45). By 1 year, death occurred in 2.46% of patients treated with heparin plus Gp IIb/IIIa blockade and in 1.89% of patients treated with bivalirudin (HR, 0.78; 95% CI, 0.55-1.11; P =.16). Nonsignificant trends toward lower 1-year mortality with bivalirudin were present in all patient subgroups analyzed and were of greatest magnitude among high-risk patients.Long-term clinical outcome with bivalirudin and provisional Gp IIb/IIIa blockade is comparable with that of heparin plus planned Gp IIb/IIIa inhibition during contemporary PCI." @default.
- W2135653600 created "2016-06-24" @default.
- W2135653600 creator A5001994412 @default.
- W2135653600 date "2004-08-11" @default.
- W2135653600 modified "2023-10-17" @default.
- W2135653600 title "Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization<SUBTITLE>REPLACE-2 Randomized Trial</SUBTITLE>" @default.
- W2135653600 cites W1489918304 @default.
- W2135653600 cites W2013018670 @default.
- W2135653600 cites W2016562783 @default.
- W2135653600 cites W2026202162 @default.
- W2135653600 cites W2038261756 @default.
- W2135653600 cites W2046359098 @default.
- W2135653600 cites W2064640871 @default.
- W2135653600 cites W2082333685 @default.
- W2135653600 cites W2102296549 @default.
- W2135653600 cites W2102695511 @default.
- W2135653600 cites W2130652855 @default.
- W2135653600 cites W2141117188 @default.
- W2135653600 cites W2153935195 @default.
- W2135653600 cites W2327850977 @default.
- W2135653600 cites W2330351728 @default.
- W2135653600 cites W2471145122 @default.
- W2135653600 doi "https://doi.org/10.1001/jama.292.6.696" @default.
- W2135653600 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15304466" @default.
- W2135653600 hasPublicationYear "2004" @default.
- W2135653600 type Work @default.
- W2135653600 sameAs 2135653600 @default.
- W2135653600 citedByCount "391" @default.
- W2135653600 countsByYear W21356536002012 @default.
- W2135653600 countsByYear W21356536002013 @default.
- W2135653600 countsByYear W21356536002014 @default.
- W2135653600 countsByYear W21356536002015 @default.
- W2135653600 countsByYear W21356536002016 @default.
- W2135653600 countsByYear W21356536002017 @default.
- W2135653600 countsByYear W21356536002018 @default.
- W2135653600 countsByYear W21356536002019 @default.
- W2135653600 countsByYear W21356536002020 @default.
- W2135653600 countsByYear W21356536002021 @default.
- W2135653600 countsByYear W21356536002022 @default.
- W2135653600 countsByYear W21356536002023 @default.
- W2135653600 crossrefType "journal-article" @default.
- W2135653600 hasAuthorship W2135653600A5001994412 @default.
- W2135653600 hasBestOaLocation W21356536001 @default.
- W2135653600 hasConcept C126322002 @default.
- W2135653600 hasConcept C164705383 @default.
- W2135653600 hasConcept C207103383 @default.
- W2135653600 hasConcept C2777557582 @default.
- W2135653600 hasConcept C2777565915 @default.
- W2135653600 hasConcept C2777871224 @default.
- W2135653600 hasConcept C2780400711 @default.
- W2135653600 hasConcept C2781056559 @default.
- W2135653600 hasConcept C42219234 @default.
- W2135653600 hasConcept C44249647 @default.
- W2135653600 hasConcept C45393284 @default.
- W2135653600 hasConcept C500558357 @default.
- W2135653600 hasConcept C71924100 @default.
- W2135653600 hasConceptScore W2135653600C126322002 @default.
- W2135653600 hasConceptScore W2135653600C164705383 @default.
- W2135653600 hasConceptScore W2135653600C207103383 @default.
- W2135653600 hasConceptScore W2135653600C2777557582 @default.
- W2135653600 hasConceptScore W2135653600C2777565915 @default.
- W2135653600 hasConceptScore W2135653600C2777871224 @default.
- W2135653600 hasConceptScore W2135653600C2780400711 @default.
- W2135653600 hasConceptScore W2135653600C2781056559 @default.
- W2135653600 hasConceptScore W2135653600C42219234 @default.
- W2135653600 hasConceptScore W2135653600C44249647 @default.
- W2135653600 hasConceptScore W2135653600C45393284 @default.
- W2135653600 hasConceptScore W2135653600C500558357 @default.
- W2135653600 hasConceptScore W2135653600C71924100 @default.
- W2135653600 hasIssue "6" @default.
- W2135653600 hasLocation W21356536001 @default.
- W2135653600 hasLocation W21356536002 @default.
- W2135653600 hasOpenAccess W2135653600 @default.
- W2135653600 hasPrimaryLocation W21356536001 @default.
- W2135653600 hasRelatedWork W103736013 @default.
- W2135653600 hasRelatedWork W2024367021 @default.
- W2135653600 hasRelatedWork W2135543305 @default.
- W2135653600 hasRelatedWork W2163292105 @default.
- W2135653600 hasRelatedWork W2375584960 @default.
- W2135653600 hasRelatedWork W2552017037 @default.
- W2135653600 hasRelatedWork W2619182563 @default.
- W2135653600 hasRelatedWork W2740454508 @default.
- W2135653600 hasRelatedWork W4239474048 @default.
- W2135653600 hasRelatedWork W4240108578 @default.
- W2135653600 hasVolume "292" @default.
- W2135653600 isParatext "false" @default.
- W2135653600 isRetracted "false" @default.
- W2135653600 magId "2135653600" @default.
- W2135653600 workType "article" @default.